<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615532</url>
  </required_header>
  <id_info>
    <org_study_id>18222</org_study_id>
    <secondary_id>I8H-MC-BDDD</secondary_id>
    <nct_id>NCT05615532</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of LY3209590 in Healthy Participants</brief_title>
  <official_title>Effect of Injection Site on the Relative Bioavailability of Single Dose of LY3209590 and Evaluation of Absolute Bioavailability of LY3209590 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in two parts (part A and part B). The main purpose of this study&#xD;
      is to compare the amount of LY3209590 that gets into the blood stream and how long it takes&#xD;
      the body to get rid of it, when self-administered at different body sites, abdominal wall,&#xD;
      upper arm and thigh (part A), when administered by two different routes of injection,&#xD;
      subcutaneously or intravenously (part B) in healthy participants.&#xD;
&#xD;
      The study may last up to 65 (part A) and 184 (part B) days, respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 11, 2022</start_date>
  <completion_date type="Anticipated">June 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A is Parallel design and Part B is a crossover design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3209590</measure>
    <time_frame>Predose on Day 1 through Day 65</time_frame>
    <description>Part A: PK: AUC0-∞ of LY3209590</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: PK: AUC0-∞ of LY3209590</measure>
    <time_frame>Predose on Day 1 through Day 65</time_frame>
    <description>Part B: PK: AUC0-∞ of LY3209590</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3209590 (Part A - Upper Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered subcutaneously (SC) into the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 (Part A - Thigh)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered SC into the thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 (Part A - Abdominal Wall)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered SC into the abdominal wall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 (Part B - IV Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 (Part B - SC Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered SC into the abdominal wall</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3209590 (SC)</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3209590 (Part A - Abdominal Wall)</arm_group_label>
    <arm_group_label>LY3209590 (Part A - Thigh)</arm_group_label>
    <arm_group_label>LY3209590 (Part A - Upper Arm)</arm_group_label>
    <arm_group_label>LY3209590 (Part B - SC Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3209590 (IV)</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3209590 (Part B - IV Dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants who are overtly healthy as determined by medical&#xD;
             evaluation&#xD;
&#xD;
          -  Participants with body mass index (BMI) within the range 18.5 to 35.0 kilograms per&#xD;
             meter squared (kg/m²)&#xD;
&#xD;
          -  Male or female participants must agree to use contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of multiple or severe allergic reactions or a history of severe&#xD;
             anaphylactic reaction&#xD;
&#xD;
          -  Have known allergies to LY3209590, related compounds, or any components of the&#xD;
             formulation&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram&#xD;
&#xD;
          -  Intend to use prescription medication, including herbal medications and traditional&#xD;
             medications&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus infection or positive human&#xD;
             immunodeficiency virus antibodies, hepatitis C or positive hepatitis C antibody, or&#xD;
             hepatitis B or positive hepatitis B surface antigen&#xD;
&#xD;
          -  Are lactating or pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 1, 2023</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>May 8, 2023</last_update_submitted>
  <last_update_submitted_qc>May 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Injection sites</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

